Requisition update
RNS & Investor News
2024
Director's Dealing
16 March 2020
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that it received notification on 12 March 2020 that Frédéric Narbel, a Director of the Company, acquired 25,700 ordinary shares in the Company on 12 March 2020, representing 0.03% of the Company's issued share capital, at an average price of 39.37 pence per share.
Following the transaction, Mr Narbel is interested in 54,700 ordinary shares in the Company, representing 0.06% of the Company's issued share capital.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
| OptiBiotix Health plc | www.optibiotix.com |
| Stephen O'Hara, Chief Executive | Contact via Walbrook below |
| Cairn Financial Advisers LLP (NOMAD) | |
| Liam Murray / Jo Turner / Ludovico Lazzaretti | Tel: 020 7213 0880 |
| finnCap (Broker) | |
| Geoff Nash / Kate Bannatyne (Corporate Finance) Camille Gochez (Corporate Broking) |
Tel: 020 7220 0500 |
| goetzpartner securities Limited | Tel: 020 3859 7725 |
| Ulrich Kinzel | |
| Walbrook PR Ltd | |
| Anna Dunphy | Mob: 07876 741 001 |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a. | Name | Frédéric AndréNarbel | |||
| 2 | Reason for notification | ||||
| a. | Position/Status | Director of the Company | |||
| b. | Initial notification/ Amendment | Initial Notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a. | Name | OptiBiotix Health Plc | |||
| b. | LEI | 213800UKYQFT941QHS14 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a. | Description of the financial instrument, type of instrument Identification Code |
25,700 ordinary shares of 2p each ISIN: GB00BP0RTP38 |
|||
| b. | Nature of the transaction | Purchase of 25,700 ordinary shares in the Company | |||
| c. | Price(s) and volume(s) | ||||
| Price(s) per share | Volume(s) | ||||
| 39.5p 38.4p | 22,500 3,200 | ||||
| d. | Aggregated information - Volume - Price |
25,700 39.37p |
|||
| e. | Date of the transaction | 12 March 2020 | |||
| f. | Place of the transaction | London Stock Exchange, AIM | |||
2023
Director's Dealing
16 March 2020
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that it received notification on 12 March 2020 that Frédéric Narbel, a Director of the Company, acquired 25,700 ordinary shares in the Company on 12 March 2020, representing 0.03% of the Company's issued share capital, at an average price of 39.37 pence per share.
Following the transaction, Mr Narbel is interested in 54,700 ordinary shares in the Company, representing 0.06% of the Company's issued share capital.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
| OptiBiotix Health plc | www.optibiotix.com |
| Stephen O'Hara, Chief Executive | Contact via Walbrook below |
| Cairn Financial Advisers LLP (NOMAD) | |
| Liam Murray / Jo Turner / Ludovico Lazzaretti | Tel: 020 7213 0880 |
| finnCap (Broker) | |
| Geoff Nash / Kate Bannatyne (Corporate Finance) Camille Gochez (Corporate Broking) |
Tel: 020 7220 0500 |
| goetzpartner securities Limited | Tel: 020 3859 7725 |
| Ulrich Kinzel | |
| Walbrook PR Ltd | |
| Anna Dunphy | Mob: 07876 741 001 |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a. | Name | Frédéric AndréNarbel | |||
| 2 | Reason for notification | ||||
| a. | Position/Status | Director of the Company | |||
| b. | Initial notification/ Amendment | Initial Notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a. | Name | OptiBiotix Health Plc | |||
| b. | LEI | 213800UKYQFT941QHS14 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a. | Description of the financial instrument, type of instrument Identification Code |
25,700 ordinary shares of 2p each ISIN: GB00BP0RTP38 |
|||
| b. | Nature of the transaction | Purchase of 25,700 ordinary shares in the Company | |||
| c. | Price(s) and volume(s) | ||||
| Price(s) per share | Volume(s) | ||||
| 39.5p 38.4p | 22,500 3,200 | ||||
| d. | Aggregated information - Volume - Price |
25,700 39.37p |
|||
| e. | Date of the transaction | 12 March 2020 | |||
| f. | Place of the transaction | London Stock Exchange, AIM | |||
2022
Director's Dealing
16 March 2020
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that it received notification on 12 March 2020 that Frédéric Narbel, a Director of the Company, acquired 25,700 ordinary shares in the Company on 12 March 2020, representing 0.03% of the Company's issued share capital, at an average price of 39.37 pence per share.
Following the transaction, Mr Narbel is interested in 54,700 ordinary shares in the Company, representing 0.06% of the Company's issued share capital.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
| OptiBiotix Health plc | www.optibiotix.com |
| Stephen O'Hara, Chief Executive | Contact via Walbrook below |
| Cairn Financial Advisers LLP (NOMAD) | |
| Liam Murray / Jo Turner / Ludovico Lazzaretti | Tel: 020 7213 0880 |
| finnCap (Broker) | |
| Geoff Nash / Kate Bannatyne (Corporate Finance) Camille Gochez (Corporate Broking) |
Tel: 020 7220 0500 |
| goetzpartner securities Limited | Tel: 020 3859 7725 |
| Ulrich Kinzel | |
| Walbrook PR Ltd | |
| Anna Dunphy | Mob: 07876 741 001 |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a. | Name | Frédéric AndréNarbel | |||
| 2 | Reason for notification | ||||
| a. | Position/Status | Director of the Company | |||
| b. | Initial notification/ Amendment | Initial Notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a. | Name | OptiBiotix Health Plc | |||
| b. | LEI | 213800UKYQFT941QHS14 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a. | Description of the financial instrument, type of instrument Identification Code |
25,700 ordinary shares of 2p each ISIN: GB00BP0RTP38 |
|||
| b. | Nature of the transaction | Purchase of 25,700 ordinary shares in the Company | |||
| c. | Price(s) and volume(s) | ||||
| Price(s) per share | Volume(s) | ||||
| 39.5p 38.4p | 22,500 3,200 | ||||
| d. | Aggregated information - Volume - Price |
25,700 39.37p |
|||
| e. | Date of the transaction | 12 March 2020 | |||
| f. | Place of the transaction | London Stock Exchange, AIM | |||
2021
Director's Dealing
16 March 2020
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that it received notification on 12 March 2020 that Frédéric Narbel, a Director of the Company, acquired 25,700 ordinary shares in the Company on 12 March 2020, representing 0.03% of the Company's issued share capital, at an average price of 39.37 pence per share.
Following the transaction, Mr Narbel is interested in 54,700 ordinary shares in the Company, representing 0.06% of the Company's issued share capital.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
| OptiBiotix Health plc | www.optibiotix.com |
| Stephen O'Hara, Chief Executive | Contact via Walbrook below |
| Cairn Financial Advisers LLP (NOMAD) | |
| Liam Murray / Jo Turner / Ludovico Lazzaretti | Tel: 020 7213 0880 |
| finnCap (Broker) | |
| Geoff Nash / Kate Bannatyne (Corporate Finance) Camille Gochez (Corporate Broking) |
Tel: 020 7220 0500 |
| goetzpartner securities Limited | Tel: 020 3859 7725 |
| Ulrich Kinzel | |
| Walbrook PR Ltd | |
| Anna Dunphy | Mob: 07876 741 001 |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a. | Name | Frédéric AndréNarbel | |||
| 2 | Reason for notification | ||||
| a. | Position/Status | Director of the Company | |||
| b. | Initial notification/ Amendment | Initial Notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a. | Name | OptiBiotix Health Plc | |||
| b. | LEI | 213800UKYQFT941QHS14 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a. | Description of the financial instrument, type of instrument Identification Code |
25,700 ordinary shares of 2p each ISIN: GB00BP0RTP38 |
|||
| b. | Nature of the transaction | Purchase of 25,700 ordinary shares in the Company | |||
| c. | Price(s) and volume(s) | ||||
| Price(s) per share | Volume(s) | ||||
| 39.5p 38.4p | 22,500 3,200 | ||||
| d. | Aggregated information - Volume - Price |
25,700 39.37p |
|||
| e. | Date of the transaction | 12 March 2020 | |||
| f. | Place of the transaction | London Stock Exchange, AIM | |||
2020
Director's Dealing
16 March 2020
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that it received notification on 12 March 2020 that Frédéric Narbel, a Director of the Company, acquired 25,700 ordinary shares in the Company on 12 March 2020, representing 0.03% of the Company's issued share capital, at an average price of 39.37 pence per share.
Following the transaction, Mr Narbel is interested in 54,700 ordinary shares in the Company, representing 0.06% of the Company's issued share capital.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
| OptiBiotix Health plc | www.optibiotix.com |
| Stephen O'Hara, Chief Executive | Contact via Walbrook below |
| Cairn Financial Advisers LLP (NOMAD) | |
| Liam Murray / Jo Turner / Ludovico Lazzaretti | Tel: 020 7213 0880 |
| finnCap (Broker) | |
| Geoff Nash / Kate Bannatyne (Corporate Finance) Camille Gochez (Corporate Broking) |
Tel: 020 7220 0500 |
| goetzpartner securities Limited | Tel: 020 3859 7725 |
| Ulrich Kinzel | |
| Walbrook PR Ltd | |
| Anna Dunphy | Mob: 07876 741 001 |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a. | Name | Frédéric AndréNarbel | |||
| 2 | Reason for notification | ||||
| a. | Position/Status | Director of the Company | |||
| b. | Initial notification/ Amendment | Initial Notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a. | Name | OptiBiotix Health Plc | |||
| b. | LEI | 213800UKYQFT941QHS14 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a. | Description of the financial instrument, type of instrument Identification Code |
25,700 ordinary shares of 2p each ISIN: GB00BP0RTP38 |
|||
| b. | Nature of the transaction | Purchase of 25,700 ordinary shares in the Company | |||
| c. | Price(s) and volume(s) | ||||
| Price(s) per share | Volume(s) | ||||
| 39.5p 38.4p | 22,500 3,200 | ||||
| d. | Aggregated information - Volume - Price |
25,700 39.37p |
|||
| e. | Date of the transaction | 12 March 2020 | |||
| f. | Place of the transaction | London Stock Exchange, AIM | |||
2019
Director's Dealing
16 March 2020
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that it received notification on 12 March 2020 that Frédéric Narbel, a Director of the Company, acquired 25,700 ordinary shares in the Company on 12 March 2020, representing 0.03% of the Company's issued share capital, at an average price of 39.37 pence per share.
Following the transaction, Mr Narbel is interested in 54,700 ordinary shares in the Company, representing 0.06% of the Company's issued share capital.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
| OptiBiotix Health plc | www.optibiotix.com |
| Stephen O'Hara, Chief Executive | Contact via Walbrook below |
| Cairn Financial Advisers LLP (NOMAD) | |
| Liam Murray / Jo Turner / Ludovico Lazzaretti | Tel: 020 7213 0880 |
| finnCap (Broker) | |
| Geoff Nash / Kate Bannatyne (Corporate Finance) Camille Gochez (Corporate Broking) |
Tel: 020 7220 0500 |
| goetzpartner securities Limited | Tel: 020 3859 7725 |
| Ulrich Kinzel | |
| Walbrook PR Ltd | |
| Anna Dunphy | Mob: 07876 741 001 |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a. | Name | Frédéric AndréNarbel | |||
| 2 | Reason for notification | ||||
| a. | Position/Status | Director of the Company | |||
| b. | Initial notification/ Amendment | Initial Notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a. | Name | OptiBiotix Health Plc | |||
| b. | LEI | 213800UKYQFT941QHS14 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a. | Description of the financial instrument, type of instrument Identification Code |
25,700 ordinary shares of 2p each ISIN: GB00BP0RTP38 |
|||
| b. | Nature of the transaction | Purchase of 25,700 ordinary shares in the Company | |||
| c. | Price(s) and volume(s) | ||||
| Price(s) per share | Volume(s) | ||||
| 39.5p 38.4p | 22,500 3,200 | ||||
| d. | Aggregated information - Volume - Price |
25,700 39.37p |
|||
| e. | Date of the transaction | 12 March 2020 | |||
| f. | Place of the transaction | London Stock Exchange, AIM | |||
2018
Director's Dealing
16 March 2020
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that it received notification on 12 March 2020 that Frédéric Narbel, a Director of the Company, acquired 25,700 ordinary shares in the Company on 12 March 2020, representing 0.03% of the Company's issued share capital, at an average price of 39.37 pence per share.
Following the transaction, Mr Narbel is interested in 54,700 ordinary shares in the Company, representing 0.06% of the Company's issued share capital.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
| OptiBiotix Health plc | www.optibiotix.com |
| Stephen O'Hara, Chief Executive | Contact via Walbrook below |
| Cairn Financial Advisers LLP (NOMAD) | |
| Liam Murray / Jo Turner / Ludovico Lazzaretti | Tel: 020 7213 0880 |
| finnCap (Broker) | |
| Geoff Nash / Kate Bannatyne (Corporate Finance) Camille Gochez (Corporate Broking) |
Tel: 020 7220 0500 |
| goetzpartner securities Limited | Tel: 020 3859 7725 |
| Ulrich Kinzel | |
| Walbrook PR Ltd | |
| Anna Dunphy | Mob: 07876 741 001 |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a. | Name | Frédéric AndréNarbel | |||
| 2 | Reason for notification | ||||
| a. | Position/Status | Director of the Company | |||
| b. | Initial notification/ Amendment | Initial Notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a. | Name | OptiBiotix Health Plc | |||
| b. | LEI | 213800UKYQFT941QHS14 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a. | Description of the financial instrument, type of instrument Identification Code |
25,700 ordinary shares of 2p each ISIN: GB00BP0RTP38 |
|||
| b. | Nature of the transaction | Purchase of 25,700 ordinary shares in the Company | |||
| c. | Price(s) and volume(s) | ||||
| Price(s) per share | Volume(s) | ||||
| 39.5p 38.4p | 22,500 3,200 | ||||
| d. | Aggregated information - Volume - Price |
25,700 39.37p |
|||
| e. | Date of the transaction | 12 March 2020 | |||
| f. | Place of the transaction | London Stock Exchange, AIM | |||
2017
Director's Dealing
16 March 2020
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that it received notification on 12 March 2020 that Frédéric Narbel, a Director of the Company, acquired 25,700 ordinary shares in the Company on 12 March 2020, representing 0.03% of the Company's issued share capital, at an average price of 39.37 pence per share.
Following the transaction, Mr Narbel is interested in 54,700 ordinary shares in the Company, representing 0.06% of the Company's issued share capital.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
| OptiBiotix Health plc | www.optibiotix.com |
| Stephen O'Hara, Chief Executive | Contact via Walbrook below |
| Cairn Financial Advisers LLP (NOMAD) | |
| Liam Murray / Jo Turner / Ludovico Lazzaretti | Tel: 020 7213 0880 |
| finnCap (Broker) | |
| Geoff Nash / Kate Bannatyne (Corporate Finance) Camille Gochez (Corporate Broking) |
Tel: 020 7220 0500 |
| goetzpartner securities Limited | Tel: 020 3859 7725 |
| Ulrich Kinzel | |
| Walbrook PR Ltd | |
| Anna Dunphy | Mob: 07876 741 001 |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a. | Name | Frédéric AndréNarbel | |||
| 2 | Reason for notification | ||||
| a. | Position/Status | Director of the Company | |||
| b. | Initial notification/ Amendment | Initial Notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a. | Name | OptiBiotix Health Plc | |||
| b. | LEI | 213800UKYQFT941QHS14 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a. | Description of the financial instrument, type of instrument Identification Code |
25,700 ordinary shares of 2p each ISIN: GB00BP0RTP38 |
|||
| b. | Nature of the transaction | Purchase of 25,700 ordinary shares in the Company | |||
| c. | Price(s) and volume(s) | ||||
| Price(s) per share | Volume(s) | ||||
| 39.5p 38.4p | 22,500 3,200 | ||||
| d. | Aggregated information - Volume - Price |
25,700 39.37p |
|||
| e. | Date of the transaction | 12 March 2020 | |||
| f. | Place of the transaction | London Stock Exchange, AIM | |||
2016
Director's Dealing
16 March 2020
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that it received notification on 12 March 2020 that Frédéric Narbel, a Director of the Company, acquired 25,700 ordinary shares in the Company on 12 March 2020, representing 0.03% of the Company's issued share capital, at an average price of 39.37 pence per share.
Following the transaction, Mr Narbel is interested in 54,700 ordinary shares in the Company, representing 0.06% of the Company's issued share capital.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
| OptiBiotix Health plc | www.optibiotix.com |
| Stephen O'Hara, Chief Executive | Contact via Walbrook below |
| Cairn Financial Advisers LLP (NOMAD) | |
| Liam Murray / Jo Turner / Ludovico Lazzaretti | Tel: 020 7213 0880 |
| finnCap (Broker) | |
| Geoff Nash / Kate Bannatyne (Corporate Finance) Camille Gochez (Corporate Broking) |
Tel: 020 7220 0500 |
| goetzpartner securities Limited | Tel: 020 3859 7725 |
| Ulrich Kinzel | |
| Walbrook PR Ltd | |
| Anna Dunphy | Mob: 07876 741 001 |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a. | Name | Frédéric AndréNarbel | |||
| 2 | Reason for notification | ||||
| a. | Position/Status | Director of the Company | |||
| b. | Initial notification/ Amendment | Initial Notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a. | Name | OptiBiotix Health Plc | |||
| b. | LEI | 213800UKYQFT941QHS14 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a. | Description of the financial instrument, type of instrument Identification Code |
25,700 ordinary shares of 2p each ISIN: GB00BP0RTP38 |
|||
| b. | Nature of the transaction | Purchase of 25,700 ordinary shares in the Company | |||
| c. | Price(s) and volume(s) | ||||
| Price(s) per share | Volume(s) | ||||
| 39.5p 38.4p | 22,500 3,200 | ||||
| d. | Aggregated information - Volume - Price |
25,700 39.37p |
|||
| e. | Date of the transaction | 12 March 2020 | |||
| f. | Place of the transaction | London Stock Exchange, AIM | |||
2015
Director's Dealing
16 March 2020
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that it received notification on 12 March 2020 that Frédéric Narbel, a Director of the Company, acquired 25,700 ordinary shares in the Company on 12 March 2020, representing 0.03% of the Company's issued share capital, at an average price of 39.37 pence per share.
Following the transaction, Mr Narbel is interested in 54,700 ordinary shares in the Company, representing 0.06% of the Company's issued share capital.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
| OptiBiotix Health plc | www.optibiotix.com |
| Stephen O'Hara, Chief Executive | Contact via Walbrook below |
| Cairn Financial Advisers LLP (NOMAD) | |
| Liam Murray / Jo Turner / Ludovico Lazzaretti | Tel: 020 7213 0880 |
| finnCap (Broker) | |
| Geoff Nash / Kate Bannatyne (Corporate Finance) Camille Gochez (Corporate Broking) |
Tel: 020 7220 0500 |
| goetzpartner securities Limited | Tel: 020 3859 7725 |
| Ulrich Kinzel | |
| Walbrook PR Ltd | |
| Anna Dunphy | Mob: 07876 741 001 |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a. | Name | Frédéric AndréNarbel | |||
| 2 | Reason for notification | ||||
| a. | Position/Status | Director of the Company | |||
| b. | Initial notification/ Amendment | Initial Notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a. | Name | OptiBiotix Health Plc | |||
| b. | LEI | 213800UKYQFT941QHS14 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a. | Description of the financial instrument, type of instrument Identification Code |
25,700 ordinary shares of 2p each ISIN: GB00BP0RTP38 |
|||
| b. | Nature of the transaction | Purchase of 25,700 ordinary shares in the Company | |||
| c. | Price(s) and volume(s) | ||||
| Price(s) per share | Volume(s) | ||||
| 39.5p 38.4p | 22,500 3,200 | ||||
| d. | Aggregated information - Volume - Price |
25,700 39.37p |
|||
| e. | Date of the transaction | 12 March 2020 | |||
| f. | Place of the transaction | London Stock Exchange, AIM | |||
2014
Director's Dealing
16 March 2020
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that it received notification on 12 March 2020 that Frédéric Narbel, a Director of the Company, acquired 25,700 ordinary shares in the Company on 12 March 2020, representing 0.03% of the Company's issued share capital, at an average price of 39.37 pence per share.
Following the transaction, Mr Narbel is interested in 54,700 ordinary shares in the Company, representing 0.06% of the Company's issued share capital.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
| OptiBiotix Health plc | www.optibiotix.com |
| Stephen O'Hara, Chief Executive | Contact via Walbrook below |
| Cairn Financial Advisers LLP (NOMAD) | |
| Liam Murray / Jo Turner / Ludovico Lazzaretti | Tel: 020 7213 0880 |
| finnCap (Broker) | |
| Geoff Nash / Kate Bannatyne (Corporate Finance) Camille Gochez (Corporate Broking) |
Tel: 020 7220 0500 |
| goetzpartner securities Limited | Tel: 020 3859 7725 |
| Ulrich Kinzel | |
| Walbrook PR Ltd | |
| Anna Dunphy | Mob: 07876 741 001 |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a. | Name | Frédéric AndréNarbel | |||
| 2 | Reason for notification | ||||
| a. | Position/Status | Director of the Company | |||
| b. | Initial notification/ Amendment | Initial Notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a. | Name | OptiBiotix Health Plc | |||
| b. | LEI | 213800UKYQFT941QHS14 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a. | Description of the financial instrument, type of instrument Identification Code |
25,700 ordinary shares of 2p each ISIN: GB00BP0RTP38 |
|||
| b. | Nature of the transaction | Purchase of 25,700 ordinary shares in the Company | |||
| c. | Price(s) and volume(s) | ||||
| Price(s) per share | Volume(s) | ||||
| 39.5p 38.4p | 22,500 3,200 | ||||
| d. | Aggregated information - Volume - Price |
25,700 39.37p |
|||
| e. | Date of the transaction | 12 March 2020 | |||
| f. | Place of the transaction | London Stock Exchange, AIM | |||
2013
Director's Dealing
16 March 2020
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that it received notification on 12 March 2020 that Frédéric Narbel, a Director of the Company, acquired 25,700 ordinary shares in the Company on 12 March 2020, representing 0.03% of the Company's issued share capital, at an average price of 39.37 pence per share.
Following the transaction, Mr Narbel is interested in 54,700 ordinary shares in the Company, representing 0.06% of the Company's issued share capital.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
| OptiBiotix Health plc | www.optibiotix.com |
| Stephen O'Hara, Chief Executive | Contact via Walbrook below |
| Cairn Financial Advisers LLP (NOMAD) | |
| Liam Murray / Jo Turner / Ludovico Lazzaretti | Tel: 020 7213 0880 |
| finnCap (Broker) | |
| Geoff Nash / Kate Bannatyne (Corporate Finance) Camille Gochez (Corporate Broking) |
Tel: 020 7220 0500 |
| goetzpartner securities Limited | Tel: 020 3859 7725 |
| Ulrich Kinzel | |
| Walbrook PR Ltd | |
| Anna Dunphy | Mob: 07876 741 001 |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a. | Name | Frédéric AndréNarbel | |||
| 2 | Reason for notification | ||||
| a. | Position/Status | Director of the Company | |||
| b. | Initial notification/ Amendment | Initial Notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a. | Name | OptiBiotix Health Plc | |||
| b. | LEI | 213800UKYQFT941QHS14 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a. | Description of the financial instrument, type of instrument Identification Code |
25,700 ordinary shares of 2p each ISIN: GB00BP0RTP38 |
|||
| b. | Nature of the transaction | Purchase of 25,700 ordinary shares in the Company | |||
| c. | Price(s) and volume(s) | ||||
| Price(s) per share | Volume(s) | ||||
| 39.5p 38.4p | 22,500 3,200 | ||||
| d. | Aggregated information - Volume - Price |
25,700 39.37p |
|||
| e. | Date of the transaction | 12 March 2020 | |||
| f. | Place of the transaction | London Stock Exchange, AIM | |||
Latest RNS News
Latest Video
ProBiotix Health anticipating "big commercial opportunities" during 2023
Group CEO Stephen O’Hara and CEO Steen Anderson | 04 January 2023
www.proactiveinvestors.co.uk
Latest Podcast
Stephen OHara interview with Investors Champion
Stephen O'Hara | 04 Jul 2019
www.investorschampion.com